Cargando…
High-risk MDS after HMAs
Autor principal: | Adès, Lionel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8925703/ https://www.ncbi.nlm.nih.gov/pubmed/35309800 http://dx.doi.org/10.1097/HS9.0000000000000219 |
Ejemplares similares
-
The impact of spliceosome mutations in MDS
por: Boultwood, Jacqueline, et al.
Publicado: (2019) -
The role of innate immunity in MDS pathogenesis
por: Sallman, David A., et al.
Publicado: (2019) -
High transferrin saturation predicts inferior clinical outcomes in patients with myelodysplastic syndromes
por: Teichman, Jennifer, et al.
Publicado: (2022) -
Routine clinical parameters and laboratory testing predict therapy-related myeloid neoplasms after treatment for breast cancer
por: Petrone, Giulia, et al.
Publicado: (2022) -
Myelodysplastic Syndromes (MDS) & COVID-19: Clinical Experience from the US Epicenter of the Pandemic
por: Feld, Jonathan, et al.
Publicado: (2020)